Tesamorelin 20mg — Vial Spec, Reconstitution Math & COA

Overview of Tesamorelin 20mg Vial Specifications & Laboratory Utility

A 20mg vial of lyophilized Tesamorelin contains a trans-3-hexenoyl derivative of human growth hormone-releasing factor (GRF 1-44). Designed specifically for high-volume in vitro assays and extended preclinical animal models, the 20mg unit mass offers high-throughput screening environments reduced per-milligram handling overhead and batch-to-batch consistency across multi-week assays.

Principal investigators and laboratory managers typically select 20mg vial configurations when operating automated liquid-handling systems or running high-density receptor binding studies that consume significant peptide mass. Note that while PX1 Research maintains high-purity Tesamorelin 10mg as a primary catalog item, 20mg configurations are evaluated for custom research requirements or high-volume lab accounts. Researchers seeking standard catalog sizes can explore our comprehensive selection via /all-peptides.

Biochemical Structure and GHRH Receptor Affinity

Tesamorelin is a stabilized synthetic peptide comprising 44 amino acids with an N-terminal trans-3-hexenoyl group. This lipophilic modification enhances enzymatic stability against dipeptidyl peptidase-IV (DPP-IV) cleavage compared to native human GHRH (1-44), thereby prolonging functional half-life in extracellular media during cell culture experiments.

Preclinical data indicate that Tesamorelin acts as a selective growth hormone-releasing hormone (GHRH) receptor agonist. Binding to GHRH receptors on anterior pituitary somatotrophs stimulates intracellular cyclic adenosine monophosphate (cAMP) accumulation through G-protein coupled signal transduction. This cascade induces the pulsatile synthesis and secretion of endogenous growth hormone (GH), which subsequently mediates insulin-like growth factor 1 (IGF-1) expression in peripheral hepatic tissue models.

Reconstitution Mathematics for a 20mg Tesamorelin Vial

Precise diluent measurement is critical when working with high-mass lyophilized cakes to ensure exact molar concentrations for volumetric pipetting. When reconstituting 20mg of purified Tesamorelin powder, researchers must account for displacement volume and target final working concentrations. Use our interactive /reconstitution-calculator to quickly verify custom volumetric requirements.

When adding 1.0 mL of sterile diluent (such as bacteriostatic water or normal saline) to 20mg of lyophilized powder, the resulting concentration is 20.0 mg/mL (20.0 µg/µL). In this concentration, a 0.05 mL (50 µL) aliquot yields 1.0 mg of active research compound.

When adding 2.0 mL of diluent to the 20mg vial, the resulting final concentration equals 10.0 mg/mL (10.0 µg/µL). In this setup, a 0.1 mL (100 µL) pipetted volume delivers 1.0 mg of peptide.

When adding 3.0 mL of diluent to the 20mg vial, the final concentration is 6.67 mg/mL (6.67 µg/µL). At this dilution, a 0.15 mL (150 µL) volume corresponds to 1.0 mg of Tesamorelin. For high-precision automated workstations, lower concentration gradients (2.0 mL to 3.0 mL) are generally preferred to minimize volumetric pipetting margin of error.

Aliquot Planning & Handling High-Mass Lyophilized Formats

Reconstituting a single 20mg vial produces a substantial amount of working peptide solution. Repeated freeze-thaw cycles subject peptide chains to mechanical shear stress and localized concentration gradients that accelerate hydrolysis and aggregation. Laboratory protocols should dictate immediate sub-aliquoting upon full reconstitution.

Following initial dissolution, the primary solution should be divided into single-use polypropylene microcentrifuge tubes according to the daily dosage or assay requirements. Aliquots intended for short-term evaluation within 48 to 72 hours should be stored at 2°C to 8°C, while those slated for long-term study must be flash-frozen and kept at -20°C or -80°C. Sterile filtering through a 0.22 µm low protein-binding PTFE syringe filter prior to aliquoting is recommended when working with non-sterile cell culture media.

Comparative Class Analysis: GHRH Analogs and GH Secretagogues

When designing protocols for somatotroph axis stimulation or tissue-repair research, investigators often evaluate Tesamorelin alongside related synthetic peptide constructs. Understanding structural and kinetic variations within the growth hormone secretagogue class informs optimal model selection.

Tesamorelin represents a modified full-length GHRH sequence designed for high receptor specificity. In contrast, CJC-1295 DAC incorporates a Maleimidopropionic acid linker that covalently binds to circulating serum albumin, dramatically extending half-life compared to short-acting GHRH derivatives. Meanwhile, Sermorelin consists of the truncated 1-29 amino acid sequence of native GHRH, offering a shorter functional half-life suitable for immediate release studies. For synergistic signaling studies, researchers frequently combine GHRH agonists with growth hormone secretagogue receptor (GHSR) ligands such as Ipamorelin to observe dual-pathway GH release dynamics in preclinical growth hormone secretagogues models.

Storage Parameters and Lyophilized Stability Matrix

Unreconstituted Tesamorelin 20mg vials are shipped in a lyoprotected, vacuum-sealed state. To maintain long-term peptide integrity, unopened vials must be stored in a dark, temperature-controlled environment. Short-term storage (under 30 days) during transit or active testing permits refrigeration at 2°C to 8°C. For extended storage exceeding 30 days, vials should be stored at -20°C or -80°C to limit background degradation.

Reconstituted solutions containing bacteriostatic water (0.9% benzyl alcohol) retain stability at 2°C to 8°C for up to 28 days under controlled laboratory conditions. Unpreserved saline solutions must be utilized within 24 hours of reconstitution to eliminate microbial proliferation risk. Detailed handling guides and stability studies are available in the PX1 /research library.

Analytical Quality Control & Lot-Matched COA Verification

High-mass vial fills demand rigid analytical verification to ensure uniform mass distribution, purity, and safety from bacterial contaminants. PX1 Research subjects every synthesis lot to independent, third-party testing in ISO 17025 accredited analytical laboratories.

Verification procedures involve High-Performance Liquid Chromatography (HPLC) to establish chemical purity (targeting ≥98.0%), coupled with Mass Spectrometry (MS) to verify molecular weight identity (target MW 5135.9 g/mol). Additionally, quantitative Chromogenic Recombinant Limulus Amebocyte Lysate (rLAL) testing measures endotoxin content, enforcing strict thresholds (<0.05 EU/mg) to prevent cell toxicity in delicate in vitro systems. Researchers can view and download lot-specific analytical documentation directly from our /coa repository.

Selecting the Optimal Format: 10mg vs 20mg Research Vials

Choosing between a 10mg and 20mg vial specification depends on research scale, experiment duration, and liquid handling capabilities. While a 20mg format offers operational efficiency for high-throughput robotics or multi-animal cohort studies, smaller fill sizes like the Tesamorelin 10mg vial reduce solution decay risks when assay runs are sporadic or short-term.

For small-scale pilot studies, utilizing 10mg vials minimizes the window in which reconstituted peptide sits in cold storage, maintaining maximum biological activity per trial. For institutional facilities managing continuous testing schedules, registering for a specialized lab account via our /wholesale portal allows access to bulk packaging, volume pricing, and customized fill configurations.